The CE Mark approval is a significant regulatory milestone that allows Medtronic to market its new pacemakers in the European market. This approval can lead to increased sales and market share in the region, which is likely to be viewed positively by investors. The advancement in technology and the benefits of the new pacemakers, such as longer battery life and easier programming, may also contribute to a competitive advantage for Medtronic. However, the impact on the stock will also depend on market conditions and investor sentiment.